175 related articles for article (PubMed ID: 7996450)
1. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212.
Fan F; Compton DR; Ward S; Melvin L; Martin BR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1383-90. PubMed ID: 7996450
[TBL] [Abstract][Full Text] [Related]
2. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
3. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development.
De Vry J; Jentzsch KR; Kuhl E; Eckel G
Behav Pharmacol; 2004 Feb; 15(1):1-12. PubMed ID: 15075621
[TBL] [Abstract][Full Text] [Related]
4. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol.
Compton DR; Gold LH; Ward SJ; Balster RL; Martin BR
J Pharmacol Exp Ther; 1992 Dec; 263(3):1118-26. PubMed ID: 1335057
[TBL] [Abstract][Full Text] [Related]
5. Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.
McMahon LR
Br J Pharmacol; 2011 Mar; 162(5):1060-73. PubMed ID: 21091643
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.
Romero J; Berrendero F; García-Gil L; Ramos JA; Fernández-Ruiz JJ
J Mol Neurosci; 1998 Oct; 11(2):109-19. PubMed ID: 10096037
[TBL] [Abstract][Full Text] [Related]
7. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
8. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs.
Martin BR; Compton DR; Thomas BF; Prescott WR; Little PJ; Razdan RK; Johnson MR; Melvin LS; Mechoulam R; Ward SJ
Pharmacol Biochem Behav; 1991 Nov; 40(3):471-8. PubMed ID: 1666911
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
10. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.
McMahon LR; Ginsburg BC; Lamb RJ
Psychopharmacology (Berl); 2008 Jul; 198(4):487-95. PubMed ID: 17673980
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.
Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR
Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759
[TBL] [Abstract][Full Text] [Related]
13. Combined Treatment with Morphine and Δ9-Tetrahydrocannabinol in Rhesus Monkeys: Antinociceptive Tolerance and Withdrawal.
Gerak LR; France CP
J Pharmacol Exp Ther; 2016 May; 357(2):357-66. PubMed ID: 26937020
[TBL] [Abstract][Full Text] [Related]
14. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.
Compton DR; Johnson MR; Melvin LS; Martin BR
J Pharmacol Exp Ther; 1992 Jan; 260(1):201-9. PubMed ID: 1309872
[TBL] [Abstract][Full Text] [Related]
17. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice.
Smith PB; Welch SP; Martin BR
J Pharmacol Exp Ther; 1994 Mar; 268(3):1381-7. PubMed ID: 8138952
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological evaluation of halogenated delta 8-THC analogs.
Charalambous A; Lin S; Marciniak G; Banijamali A; Friend FL; Compton DR; Martin BR; Makriyannis A
Pharmacol Biochem Behav; 1991 Nov; 40(3):509-12. PubMed ID: 1666915
[TBL] [Abstract][Full Text] [Related]
19. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Welch SP; Dunlow LD; Patrick GS; Razdan RK
J Pharmacol Exp Ther; 1995 Jun; 273(3):1235-44. PubMed ID: 7791096
[TBL] [Abstract][Full Text] [Related]
20. Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.
Hruba L; Ginsburg BC; McMahon LR
J Pharmacol Exp Ther; 2012 Sep; 342(3):843-9. PubMed ID: 22718500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
